Literature DB >> 30058101

Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.

Shufang Liu1, Chenghao Chu2, Alan Rong1.   

Abstract

A cancer clinical trial with an immunotherapy often has 2 special features, which are patients being potentially cured from the cancer and the immunotherapy starting to take clinical effect after a certain delay time. Existing testing methods may be inadequate for immunotherapy clinical trials, because they do not appropriately take the 2 features into consideration at the same time, hence have low power to detect the true treatment effect. In this paper, we proposed a piece-wise proportional hazards cure rate model with a random delay time to fit data, and a new weighted log-rank test to detect the treatment effect of an immunotherapy over a chemotherapy control. We showed that the proposed weight was nearly optimal under mild conditions. Our simulation study showed a substantial gain of power in the proposed test over the existing tests and robustness of the test with misspecified weight. We also introduced a sample size calculation formula to design the immunotherapy clinical trials using the proposed weighted log-rank test.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cure rate; immunotherapy; piece-wise proportional hazards cure rate model; random delayed treatment effect; sample size; weighted log-rank test

Mesh:

Year:  2018        PMID: 30058101     DOI: 10.1002/pst.1878

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  Cancer immunotherapy trial design with random delayed treatment effect and cure rate.

Authors:  Jianrong Wu; Jing Wei
Journal:  Stat Med       Date:  2021-11-15       Impact factor: 2.497

2.  On the empirical choice of the time window for restricted mean survival time.

Authors:  Lu Tian; Hua Jin; Hajime Uno; Ying Lu; Bo Huang; Keaven M Anderson; L J Wei
Journal:  Biometrics       Date:  2020-02-26       Impact factor: 2.571

3.  Cancer immunotherapy trial design with cure rate and delayed treatment effect.

Authors:  Jing Wei; Jianrong Wu
Journal:  Stat Med       Date:  2019-11-26       Impact factor: 2.497

4.  Cancer immunotherapy trial design with delayed treatment effect.

Authors:  Jianrong Wu; Jing Wei
Journal:  Pharm Stat       Date:  2019-11-15       Impact factor: 1.234

5.  Challenges of evaluating immunotherapy efficacy in solid tumors.

Authors:  Rilan Bai; Wenqian Li; Nawen Du; Jiuwei Cui
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

6.  Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.

Authors:  Robin Ristl; Nicolás M Ballarini; Heiko Götte; Armin Schüler; Martin Posch; Franz König
Journal:  Pharm Stat       Date:  2020-08-23       Impact factor: 1.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.